The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug ... popular Ozempic and Wegovy treatments — from its drug ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Like many pharma stocks, Eli Lilly (NYSE: LLY ... has been so high that it immediately landed on the FDA's drug-shortage list following approval and remained there until recently.